Results 101 to 110 of about 4,565 (213)

Antibiotic Resistance Breakers: Current Approaches and Future Directions [PDF]

, 2019
Infections of antibiotic-resistant pathogens pose an ever-increasing threat to mankind. The investigation of novel approaches for tackling the antimicrobial resistance (AMR) crisis must be part of any global response to this problem if an untimely ...
Laws, Mark Benjamin, Rahman, Khondaker Mirazur, Shaaban, Ali   +2 more
core   +2 more sources

Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil

Journal of Global Antimicrobial Resistance
Introduction: Novel beta-lactam/beta-lactamase inhibitor (BIBLI) combinations are commercially available and have been used for treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infections.
Camila Mörschbächer Wilhelm, Laura Czerkster Antochevis, Cibele Massotti Magagnin, Beatriz Arns, Tarsila Vieceli, Dariane Castro Pereira, Larissa Lutz, Ândrea Celestino de Souza, Jéssica Nesello dos Santos, Rafaela Ramalho Guerra, Gregory S. Medeiros, Lucas Santoro, Diego R. Falci, Maria Helena Rigatto, Afonso Luís Barth, Andreza Francisco Martins, Alexandre Prehn Zavascki   +16 more
doaj   +1 more source

Efficacy and Safety of Meropenem\u2013Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis [PDF]

, 2019
open5siIntroduction: Infections due to Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae are associated with increased morbidity and high mortality.
Bassetti, M., Giacobbe, D. R., Massey, J., Patel, N., Tillotson, G.   +4 more
core   +2 more sources

National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa

Antibiotics
Background: Meropenem–vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an ...
Aurélien Dinh, Alexandre Bleibtreu, Clara Duran, Frédérique Bouchand, Alexie Bosch, Jullien Crozon-Clauzel, Mariam Roncato-Saberan, Morgan Matt, André Boibieux, Annlyse Fanton, Heidi Wille, Elise Fiaux, Benoît Pilmis, Marie Lacoste, Quentin Saint-Genis, Caroline Thumerelle, Patricia Pavese, Fanny Vuotto, Eric Senneville, Anaïs Potron, Stéphane Corvec, David Boutoille, Katy Jeannot, Laurent Dortet, on behalf of the Meropenem-Vaborbactam French Study Group   +24 more
doaj   +1 more source

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians [PDF]

, 2022
Corcione, Silvia, De Rosa, Francesco, Di Bella, Stefano, Lupia, Tommaso, Stroffolini, Giacomo   +4 more
core   +1 more source

Characterization of Metallo β-Lactamase Producing Enterobacterales Isolates with Susceptibility to the Aztreonam/Avibactam Combination [PDF]

Background/Objectives: Metallo-β-lactamases (MBLs) in Enterobacterales and other Gram-negative organisms pose significant public health threats due to their association with multidrug resistance (MDR).
De Maio F., Posteraro B., Sanguinetti M., Spanu T.   +3 more
core   +1 more source

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae-Producing KPC-31, a D179Y Variant of KPC-3 [PDF]

, 2021
A 68-year-old man had recurrent bacteremia by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae resistant to ceftazidime-avibactam and cefiderocol.
Arcari G, Barnini S, Carattoli A, Falcone M, Giordano C, Leonildi A, Menichetti F., Tiseo G   +7 more
core  

In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex

Antibiotics
The Klebsiella pneumoniae complex is a commonly isolated bacteria in human infections. These opportunistic pathogens pose a serious threat to public health due to their potential transmission to the human population.
Alicja Sękowska
doaj   +1 more source

Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales

BMC Infectious Diseases
Background Bloodstream infection (BSI) is associated with poor outcomes especially when effective antimicrobial therapy and control of infection source are delayed.
Helio S. Sader, John H. Kimbrough, Rodrigo E. Mendes, Mariana Castanheira   +3 more
doaj   +1 more source

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae

Journal of Global Antimicrobial Resistance
AIM/BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a significant global threat due to the limited treatment options. In this study, in vitro activities of novel antimicrobial agents were investigated against CRKP strains ...
FATMA SENA TÜRKDOĞAN, Betigul Ongen
doaj   +1 more source